BlackRock Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

BlackRock Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$2.65M	Sell	24,262 -294	-1%	-$32.7K	﹤0.01%	2029
2016 Q3	$2.98M	Sell	24,556 -571	-2%	-$77K	﹤0.01%	1860
2016 Q2	$3.55M	Sell	25,127 -17,285	-41%	-$2.55M	﹤0.01%	1680
2016 Q1	$5.54M	Sell	42,412 -1,562	-4%	-$194K	0.01%	1311
2015 Q4	$6.18M	Buy	43,974 +9,372	+27%	+$1.3M	0.01%	1250
2015 Q3	$4.59M	Sell	34,602 -7,831	-18%	-$1.35M	0.01%	1443
2015 Q2	$7.47M	Buy	+42,433	New	+$7.62M	0.01%	1203
2015 Q1	–	Sell	-33,605	Closed	-$5.5M	–	4100
2014 Q4	$5.5M	Buy	33,605 +6,491	+24%	+$1.08M	0.01%	1299
2014 Q3	$4.35M	Buy	27,114 +5,982	+28%	+$920K	0.01%	1428
2014 Q2	$3.11M	Buy	21,132 +2,705	+15%	+$375K	﹤0.01%	1738
2014 Q1	$2.56M	Buy	18,427 +706	+4%	+$106K	﹤0.01%	1869
2013 Q4	$2.24M	Sell	17,721 -260	-1%	-$26.9K	﹤0.01%	1947
2013 Q3	$1.65M	Buy	17,981 +313	+2%	+$25.3K	﹤0.01%	2088
2013 Q2	$1.21M	Buy	+17,668	New	+$1.08M	﹤0.01%	2226

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Investment Management's JAZZ Position: Q4 2016 in Review

BlackRock Investment Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 1.2% in Q4 2016, selling an estimated $32.7K and leaving 24,262 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

BlackRock Investment Management first reported a position in JAZZ in Q2 2013 and has held it in 14 quarters since. The position peaked at $7.47M in Q2 2015. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

BlackRock Investment Management held 24,262 shares of Jazz Pharmaceuticals worth $2.65M as of Q4 2016.
BlackRock Investment Management sold 294 Jazz Pharmaceuticals shares in Q4 2016, an estimated $32.7K.
Jazz Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2029 holding.
BlackRock Investment Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
BlackRock Investment Management's Jazz Pharmaceuticals position peaked at $7.47M in Q2 2015.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.